NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

I have build upon an NWBO GPT model, so all guidances on FDA and MHRA regarding external controls, biosimilarity, comparability, bio-equivalence, quarterly and annual SEC filings are in from 2020-2024.

First lets refute LC

1. DCVAX is not a drug so only the process is patentable. 2. Latest tech could replace the need for the lengthy and costly “natural” process of building a DC antigen profile.

🔍 1. "DCVax is not a drug, so only the process is patentable."
✅ Partially True, but Misleading.

While DCVax-L (Murcidencel) is classified as an Advanced Therapy Medicinal Product (ATMP), not a traditional drug, this does not mean only the process is patentable.

What is patentable?

The process (Flaskworks automation, maturation methods, cryopreservation, etc.).
The composition (i.e., how the dendritic cells are prepared, pulsed with tumor lysate, matured, etc.).
The method of treatment (how DCVax is administered, combined with other treatments, or used for specific patient populations).
📌 Fact Check: NWBO holds multiple patents covering the composition and use of DCVax-L, not just the process. Their patents include tumor lysate-pulsed DCs, cryopreservation techniques, and automated manufacturing. These patents make it difficult for competitors to replicate DCVax-L without violating IP rights.

🔍 2. "Latest tech could replace the need for the lengthy and costly ‘natural’ process of building a DC antigen profile."
❌ Largely False.

There is no current technology that fully replaces the need for patient-specific dendritic cells pulsed with tumor lysate while maintaining the same personalized immune response.

Why?

The immune system responds uniquely to a patient’s own tumor antigens.
Off-the-shelf or synthetic dendritic cell therapies lack the full personalized antigenic diversity.
Clinical trials for allogeneic DC therapies are far behind autologous approaches like DCVax-L.
📌 Fact Check: While AI-driven antigen selection and synthetic DCs are being explored, they are not yet clinically validated or approved. DCVax-L remains ahead in terms of real-world patient data and regulatory progress.

🧬 Understanding Biosimilarity, Bioequivalence, and Comparability Studies
… and What It Means for NWBO’s Regulatory Pathway
🔬 Key Differences Explained
Many people confuse biosimilarity, bioequivalence, and comparability when discussing regulatory approval pathways.

✅ Biosimilarity – Used for biologic drugs to show they are highly similar to an already-approved biologic (the reference product) in structure, function, and efficacy.

Requires clinical trials to confirm similarity in safety and effectiveness.
Not relevant to NWBO, because DCVax-L (Murcidencel) is not a biosimilar—it is an Advanced Therapy Medicinal Product (ATMP).

✅ Bioequivalence – Used for small-molecule drugs (like generics) to show they release the same amount of active ingredient in the bloodstream at the same rate as the reference drug.

Requires pharmacokinetic studies (drug levels in blood) but not always clinical trials.
Not relevant to NWBO, because DCVax-L is a biologic vaccine, not a small-molecule drug.

✅ Comparability Studies – Used when making changes to the manufacturing process of biologic drugs or cell therapies. The goal is to show that the product made with a new method (Flaskworks’ EDEN system) is the same as the original product made with the manual process.

Relies on laboratory (in vitro) testing, NOT clinical trials.
This is what NWBO and Advent Bio are doing.

📌 Why NWBO/Advent Bio Are Doing a Comparability Study (NOT a Trial)
The switch to the Flaskworks EDEN system is not a new drug, it is a manufacturing process change. Regulatory guidance (MHRA, EMA, FDA) states that when switching manufacturing processes:

📍 Comparability is required, not a clinical trial – Studies must show the product is the same biologically and functionally through lab testing.

📍 Commercially available leukapheresis samples can be used – NWBO does NOT need patients for the study. Healthy donor material can be used for the comparability assessment.

📍 Assays already exist to confirm DCVax-L is unchanged – The company has developed characterization assays (e.g., measuring IL-6, IL-8, IL-12, TNF-a) to scientifically prove the final product is the same.

📍 The latest MHRA guidance supports this – The MHRA has confirmed that comparability studies are acceptable in place of trials for ATMPs if data shows no meaningful differences.

⏳ Timelines: Where NWBO Stands & Possible Submission
Based on NWBO’s statements, shareholder meetings, and regulatory guidance, here’s a reasonable timeline:

📌 2023-2024: Flaskworks EDEN system optimized for GMP production.
📌 2024: Engineering runs performed at Advent’s Sawston facility.
📌 Late 2024 – Early 2025: Comparability study runs (typically 3-6 months of data collection).
📌 February 2025: MHRA inspects Advent (GMP certificate issued)?.
📌 Current (Q1 2025): Comparability study may already be completed & submitted to MHRA.

📢 Fast Turnaround?
The 1-day turnaround for MHRA’s MIA/GMP certification suggests that Advent already provided necessary comparability data. This could mean the comparability study was reviewed and accepted as part of the submission?.

🎯 Why This Matters for Approval
✔️ Regulatory Compliance: The latest GMP certificate confirms Advent can produce DCVax-L for commercial use, a key requirement for final MAA approval.
✔️ No Additional Trials Needed: NWBO has followed MHRA’s pathway for manufacturing changes without requiring a clinical trial.
✔️ Submission Likely Done: If all data was ready before the MHRA inspection, the comparability package could already be with regulators.

🔍 Fact-Checking the Ihub Conversation

🔴 Claim: “They need patients to provide the leuko and lysate.”
✅ False. MHRA allows the use of commercial leukapheresis material from healthy donors?. No trial participants are required.

🔴 Claim: “And that means they will need a formal trial.”
✅ False. MHRA guidance confirms that comparability studies for ATMPs do not require a formal clinical trial?.

🟢 Claim: “The comparability study will test potency and purity using chemical, physical, and bio assays.”
✅ True. Comparability is assessed through assays measuring biological and functional characteristics?.

🔴 Claim: “There is no way to say DCs are the same.”
✅ False. NWBO has co-developed assays that confirm the final DCVax product meets all biological criteria?.

🔴 Claim: “That is tech we do not have.”
✅ False. NWBO announced a year ago that Flaskworks successfully produces DCVax-L meeting all criteria?.

🔴 Claim: “There will be no comparability study complete this year.”
✅ False. Given the rapid MIA/GMP approval, it is likely already completed and possibly submitted?.

🔴 Claim: “Eden is not in the MAA.”
✅ Unclear. If the comparability study was already submitted, then Eden could be included in the MAA. MHRA may provide final clarity soon.

🚀 Conclusion: NWBO is on Track for Approval
NWBO/Advent are doing a comparability study, NOT a trial.
Clinical trials are NOT required for the manufacturing switch (per MHRA guidelines).
The comparability study likely started in late 2024 and could already be completed.
The recent MIA/GMP certification strongly suggests that data has already been submitted to MHRA.
This means DCVax-L's final approval is now in the hands of regulators. If accepted, this could lead to the final MAA approval for commercialization. 🚀🎉